ANI Pharmaceuticals (ANIP) Stock Forecast, Price Target & Predictions
ANIP Stock Forecast
ANI Pharmaceuticals stock forecast is as follows: an average price target of $67.33 (represents a 15.07% upside from ANIP’s last price of $58.51) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
ANIP Price Target
The average price target for ANI Pharmaceuticals (ANIP) is $67.33 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $94.00 to $48.00. This represents a potential 15.07% upside from ANIP's last price of $58.51.
ANIP Analyst Ratings
According to 2 Wall Street analysts, ANI Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for ANIP stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
ANI Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 11, 2024 | Les Sulewski | Truist Financial | $60.00 | $55.48 | 8.15% | 2.55% |
| Jun 26, 2024 | Oren Livnat | H.C. Wainwright | $94.00 | $65.49 | 43.53% | 60.66% |
| May 13, 2024 | Oren Livnat | H.C. Wainwright | $87.00 | $68.06 | 27.83% | 48.69% |
| Aug 09, 2022 | - | Raymond James | $48.00 | $34.87 | 37.65% | -17.96% |
The latest ANI Pharmaceuticals stock forecast, released on Sep 11, 2024 by Les Sulewski from Truist Financial, set a price target of $60.00, which represents a 8.15% increase from the stock price at the time of the forecast ($55.48), and a 2.55% increase from ANIP last price ($58.51).
ANI Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 2 | 3 |
| Avg Price Target | $60.00 | $77.00 | $80.33 |
| Last Closing Price | $58.51 | $58.51 | $58.51 |
| Upside/Downside | 2.55% | 31.60% | 37.29% |
In the current month, the average price target of ANI Pharmaceuticals stock is $60.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 2.55% increase as opposed to ANI Pharmaceuticals's last price of $58.51. This month's average price target is down -22.08% compared to last quarter, and down -25.31% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jun 26, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| May 13, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 09, 2022 | Raymond James | Outperform | Outperform | Hold |
ANI Pharmaceuticals's last stock rating was published by H.C. Wainwright on Jun 26, 2024. The company gave ANIP a "Buy" rating, the same as its previous rate.
ANI Pharmaceuticals Financial Forecast
ANI Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $131.65M | $131.83M | $116.55M | $106.79M | $94.23M | $83.82M | - | $64.48M | $60.93M | $52.06M | $48.63M | $54.52M | $57.25M | $52.98M | $48.47M | $49.77M | $47.97M | $51.34M | $54.36M | $52.89M | $57.12M | $50.70M |
| Avg Forecast | $146.27M | $141.55M | $137.72M | $126.47M | $142.62M | $140.25M | $129.09M | $126.03M | $124.94M | $111.92M | $99.87M | $83.50M | $86.04M | $78.36M | $71.97M | $65.03M | $56.30M | $49.70M | $46.40M | $46.73M | $54.27M | $51.50M | $46.93M | $50.23M | $51.63M | $55.97M | $55.20M | $50.57M | $53.66M | $45.99M |
| High Forecast | $149.05M | $144.25M | $140.34M | $128.88M | $145.33M | $143.02M | $131.55M | $128.43M | $132.07M | $114.05M | $101.77M | $85.08M | $87.68M | $79.85M | $71.97M | $66.01M | $57.15M | $50.45M | $47.10M | $47.44M | $55.08M | $52.27M | $47.64M | $50.99M | $52.41M | $56.81M | $56.03M | $51.33M | $64.39M | $55.18M |
| Low Forecast | $144.14M | $139.49M | $135.72M | $124.63M | $140.54M | $138.31M | $127.21M | $124.20M | $121.16M | $110.29M | $98.42M | $82.28M | $84.79M | $77.22M | $71.97M | $63.71M | $55.15M | $48.69M | $45.46M | $45.78M | $53.16M | $50.45M | $45.98M | $49.21M | $50.58M | $54.83M | $54.08M | $49.54M | $42.93M | $36.79M |
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | - | 1 | 1 | 1 | 10 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 20 | 11 |
| Surprise % | - | - | - | - | - | - | - | - | 1.05% | 1.18% | 1.17% | 1.28% | 1.10% | 1.07% | - | 0.99% | 1.08% | 1.05% | 1.05% | 1.17% | 1.06% | 1.03% | 1.03% | 0.99% | 0.93% | 0.92% | 0.98% | 1.05% | 1.06% | 1.10% |
ANI Pharmaceuticals's average Quarter revenue forecast for Mar 24 based on 1 analysts is $126.03M, with a low forecast of $124.20M, and a high forecast of $128.43M. ANIP's average Quarter revenue forecast represents a -4.27% decrease compared to the company's last Quarter revenue of $131.65M (Dec 23).
ANI Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | - | 1 | 1 | 1 | 10 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 20 | 11 |
| EBITDA | - | - | - | - | - | - | - | - | $48.62M | $30.56M | $40.43M | $26.65M | $19.45M | $14.41M | - | $-3.97M | $-50.26M | $6.71M | $-4.30M | $13.43M | $11.07M | $13.93M | $-225.00K | $3.35M | $4.78M | $16.77M | $18.81M | $20.38M | $19.65M | $18.68M |
| Avg Forecast | $24.14M | $23.36M | $22.73M | $20.87M | $23.53M | $23.14M | $21.30M | $-12.40M | $20.62M | $18.47M | $16.48M | $-13.26M | $14.20M | $4.59M | $11.88M | $-14.18M | $9.29M | $3.63M | $-4.46M | $7.91M | $8.95M | $12.51M | $-267.35K | $2.79M | $5.19M | $19.11M | $16.62M | $15.52M | $18.38M | $16.77M |
| High Forecast | $24.60M | $23.80M | $23.16M | $21.27M | $23.98M | $23.60M | $21.71M | $-9.92M | $21.79M | $18.82M | $16.79M | $-10.61M | $14.47M | $5.50M | $11.88M | $-11.34M | $9.43M | $4.35M | $-3.57M | $9.49M | $9.09M | $15.01M | $-213.88K | $3.34M | $6.22M | $22.94M | $19.95M | $18.63M | $22.06M | $20.12M |
| Low Forecast | $23.79M | $23.02M | $22.40M | $20.57M | $23.19M | $22.82M | $20.99M | $-14.88M | $19.99M | $18.20M | $16.24M | $-15.91M | $13.99M | $3.67M | $11.88M | $-17.02M | $9.10M | $2.90M | $-5.36M | $6.32M | $8.77M | $10.00M | $-320.82K | $2.23M | $4.15M | $15.29M | $13.30M | $12.42M | $14.71M | $13.41M |
| Surprise % | - | - | - | - | - | - | - | - | 2.36% | 1.65% | 2.45% | -2.01% | 1.37% | 3.14% | - | 0.28% | -5.41% | 1.85% | 0.96% | 1.70% | 1.24% | 1.11% | 0.84% | 1.20% | 0.92% | 0.88% | 1.13% | 1.31% | 1.07% | 1.11% |
1 analysts predict ANIP's average Quarter EBITDA for Mar 24 to be $-12.40M, with a high of $-9.92M and a low of $-14.88M. This is -125.50% lower than ANI Pharmaceuticals's previous annual EBITDA (Dec 23) of $48.62M.
ANI Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | - | 1 | 1 | 1 | 10 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 20 | 11 |
| Net Income | - | - | - | - | - | - | - | - | $1.16M | $9.94M | $6.25M | $1.44M | $-4.24M | $-8.60M | - | $-20.13M | $-51.05M | $-4.45M | $-14.11M | $86.00K | $-3.63M | $434.00K | $-12.34M | $-7.01M | $-4.83M | $3.90M | $6.58M | $449.00K | $5.43M | $5.04M |
| Avg Forecast | $21.83M | $13.14M | $16.62M | $9.47M | $24.34M | $20.91M | $18.35M | $-52.79M | $16.52M | $16.29M | $12.88M | $-56.46M | $12.98M | $-3.04M | $4.27M | $-60.39M | $14.22M | $-2.40M | $-14.66M | $50.63K | $18.13M | $389.61K | $-14.66M | $-5.83M | $-5.24M | $4.44M | $5.82M | $342.10K | $5.08M | $4.52M |
| High Forecast | $22.37M | $13.46M | $17.03M | $9.70M | $24.95M | $22.08M | $18.81M | $-42.24M | $17.35M | $16.70M | $13.20M | $-45.17M | $13.31M | $-2.43M | $4.27M | $-48.31M | $14.50M | $-1.92M | $-11.73M | $60.76K | $18.48M | $467.54K | $-11.73M | $-4.66M | $-4.20M | $5.33M | $6.98M | $410.51K | $6.10M | $5.42M |
| Low Forecast | $21.42M | $12.89M | $16.30M | $9.29M | $23.88M | $19.17M | $18.01M | $-63.35M | $15.28M | $15.99M | $12.64M | $-67.76M | $12.74M | $-3.65M | $4.27M | $-72.47M | $13.85M | $-2.88M | $-17.59M | $40.50K | $17.65M | $311.69K | $-17.59M | $-7.00M | $-6.29M | $3.55M | $4.66M | $273.68K | $4.06M | $3.62M |
| Surprise % | - | - | - | - | - | - | - | - | 0.07% | 0.61% | 0.48% | -0.03% | -0.33% | 2.83% | - | 0.33% | -3.59% | 1.85% | 0.96% | 1.70% | -0.20% | 1.11% | 0.84% | 1.20% | 0.92% | 0.88% | 1.13% | 1.31% | 1.07% | 1.11% |
ANI Pharmaceuticals's average Quarter net income forecast for Mar 24 is $-52.79M, with a range of $-63.35M to $-42.24M. ANIP's average Quarter net income forecast represents a -4670.95% decrease compared to the company's last Quarter net income of $1.16M (Dec 23).
ANI Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | - | 1 | 1 | 1 | 10 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 20 | 11 |
| SG&A | - | - | - | - | - | - | - | - | $44.46M | $42.01M | $38.76M | $36.47M | $33.19M | $30.08M | - | $28.82M | $30.71M | $17.18M | $18.82M | $17.59M | $14.37M | $15.72M | $21.21M | $13.68M | $14.01M | $14.36M | $14.19M | $13.28M | $13.38M | $11.77M |
| Avg Forecast | $49.62M | $48.02M | $46.72M | $42.91M | $48.38M | $47.58M | $43.79M | $75.58M | $42.39M | $37.97M | $33.88M | $80.83M | $29.19M | $11.74M | $24.42M | $22.06M | $19.10M | $9.28M | $19.56M | $10.35M | $18.41M | $14.12M | $25.21M | $11.38M | $15.20M | $16.36M | $12.54M | $10.12M | $12.51M | $10.56M |
| High Forecast | $50.57M | $48.94M | $47.61M | $43.72M | $49.30M | $48.52M | $44.63M | $90.69M | $44.81M | $38.69M | $34.53M | $97.00M | $29.75M | $14.08M | $24.42M | $22.40M | $19.39M | $11.13M | $23.47M | $12.42M | $18.69M | $16.94M | $30.25M | $13.65M | $18.24M | $19.64M | $15.05M | $12.15M | $15.02M | $12.67M |
| Low Forecast | $48.90M | $47.32M | $46.04M | $42.28M | $47.68M | $46.92M | $43.16M | $60.46M | $41.10M | $37.42M | $33.39M | $64.67M | $28.77M | $9.39M | $24.42M | $21.61M | $18.71M | $7.42M | $15.65M | $8.28M | $18.04M | $11.29M | $20.16M | $9.10M | $12.16M | $13.09M | $10.03M | $8.10M | $10.01M | $8.45M |
| Surprise % | - | - | - | - | - | - | - | - | 1.05% | 1.11% | 1.14% | 0.45% | 1.14% | 2.56% | - | 1.31% | 1.61% | 1.85% | 0.96% | 1.70% | 0.78% | 1.11% | 0.84% | 1.20% | 0.92% | 0.88% | 1.13% | 1.31% | 1.07% | 1.11% |
ANI Pharmaceuticals's average Quarter SG&A projection for Mar 24 is $75.58M, based on 1 Wall Street analysts, with a range of $60.46M to $90.69M. The forecast indicates a 69.98% rise compared to ANIP last annual SG&A of $44.46M (Dec 23).
ANI Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | - | 1 | 1 | 1 | 10 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 20 | 11 |
| EPS | - | - | - | - | - | - | - | - | $0.06 | $0.46 | $0.35 | $0.06 | $-0.26 | $-0.53 | - | $-1.25 | $-3.60 | $-0.37 | $-1.17 | $0.01 | $-0.30 | $0.04 | $-1.03 | $-0.59 | $-0.41 | $0.32 | $0.55 | $0.04 | $0.46 | $0.43 |
| Avg Forecast | $1.13 | $0.68 | $0.86 | $0.49 | $1.26 | $1.08 | $0.95 | $1.00 | $0.85 | $0.84 | $0.67 | $0.35 | $0.67 | $0.55 | $0.22 | $0.09 | $0.74 | $0.70 | $0.60 | $0.71 | $0.94 | $0.88 | $0.75 | $0.89 | $1.18 | $1.43 | $1.28 | $1.05 | $1.16 | $1.05 |
| High Forecast | $1.16 | $0.70 | $0.88 | $0.50 | $1.29 | $1.14 | $0.97 | $1.02 | $0.90 | $0.86 | $0.68 | $0.36 | $0.69 | $0.57 | $0.22 | $0.10 | $0.75 | $0.71 | $0.62 | $0.72 | $0.96 | $0.90 | $0.76 | $0.91 | $1.21 | $1.46 | $1.31 | $1.07 | $1.39 | $1.26 |
| Low Forecast | $1.11 | $0.67 | $0.84 | $0.48 | $1.24 | $0.99 | $0.93 | $0.98 | $0.79 | $0.83 | $0.65 | $0.35 | $0.66 | $0.54 | $0.22 | $0.09 | $0.72 | $0.68 | $0.59 | $0.69 | $0.92 | $0.86 | $0.73 | $0.87 | $1.15 | $1.39 | $1.25 | $1.02 | $0.93 | $0.84 |
| Surprise % | - | - | - | - | - | - | - | - | 0.07% | 0.55% | 0.52% | 0.17% | -0.39% | -0.96% | - | -13.39% | -4.86% | -0.53% | -1.93% | 0.01% | -0.32% | 0.05% | -1.38% | -0.66% | -0.35% | 0.22% | 0.43% | 0.04% | 0.40% | 0.41% |
According to 1 Wall Street analysts, ANI Pharmaceuticals's projected average Quarter EPS for Mar 24 is $1.00, with a low estimate of $0.98 and a high estimate of $1.02. This represents a 1557.24% increase compared to ANIP previous annual EPS of $0.06 (Dec 23).
ANI Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PROC | Procaps Group | $1.85 | $10.00 | 440.54% | - |
| PCRX | Pacira BioSciences | $13.11 | $43.00 | 227.99% | Hold |
| IRWD | Ironwood Pharmaceuticals | $4.57 | $11.67 | 155.36% | Buy |
| AMPH | Amphastar Pharmaceuticals | $48.09 | $66.00 | 37.24% | Buy |
| ALKS | Alkermes | $27.66 | $35.50 | 28.34% | Buy |
| NBIX | Neurocrine Biosciences | $122.25 | $146.60 | 19.92% | Buy |
| ANIP | ANI Pharmaceuticals | $58.51 | $67.33 | 15.07% | Buy |
| COLL | Collegium Pharmaceutical | $37.50 | $41.50 | 10.67% | Buy |
| PBH | Prestige Consumer Healthcare | $74.12 | $82.00 | 10.63% | Buy |
| DCPH | Deciphera Pharmaceuticals | $25.59 | $26.32 | 2.85% | Hold |
| PAHC | Phibro Animal Health | $21.99 | $18.67 | -15.10% | Buy |
ANIP Forecast FAQ
Is ANI Pharmaceuticals a good buy?
Yes, according to 2 Wall Street analysts, ANI Pharmaceuticals (ANIP) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of ANIP's total ratings.
What is ANIP's price target?
ANI Pharmaceuticals (ANIP) average price target is $67.33 with a range of $48 to $94, implying a 15.07% from its last price of $58.51. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will ANI Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for ANIP stock, the company can go up by 15.07% (from the last price of $58.51 to the average price target of $67.33), up by 60.66% based on the highest stock price target, and down by -17.96% based on the lowest stock price target.
Can ANI Pharmaceuticals stock reach $90?
ANIP's highest twelve months analyst stock price target of $94 supports the claim that ANI Pharmaceuticals can reach $90 in the near future.
What is ANI Pharmaceuticals's current price target trend?
1 Wall Street analyst forecast a $60 price target for ANI Pharmaceuticals (ANIP) this month, up 2.55% from its last price of $58.51. Compared to the last 3 and 12 months, the average price target increased by 31.60% and increased by 37.29%, respectively.
What are ANI Pharmaceuticals's analysts' financial forecasts?
ANI Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $537.99M (high $548.32M, low $530.26M), average EBITDA is $55.58M (high $59.37M, low $52.13M), average net income is $10.82M (high $23.6M, low $-2.289M), average SG&A $215.34M (high $233.15M, low $198.22M), and average EPS is $4.29 (high $4.43, low $4.14). ANIP's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $552.01M (high $562.52M, low $543.98M), average EBITDA is $91.09M (high $92.83M, low $89.77M), average net income is $61.05M (high $62.57M, low $59.9M), average SG&A $187.28M (high $190.84M, low $184.55M), and average EPS is $3.16 (high $3.24, low $3.1).
Did the ANIP's actual financial results beat the analysts' financial forecasts?
Based on ANI Pharmaceuticals's last annual report (Dec 2023), the company's revenue was $486.82M, beating the average analysts forecast of $420.22M by 15.85%. Apple's EBITDA was $174.44M, beating the average prediction of $42.31M by 312.33%. The company's net income was $18.78M, missing the average estimation of $-10.77M by -274.36%. Apple's SG&A was $161.7M, missing the average forecast of $195.07M by -17.11%. Lastly, the company's EPS was $1.03, missing the average prediction of $2.72 by -62.09%. In terms of the last quarterly report (Dec 2023), ANI Pharmaceuticals's revenue was $131.65M, beating the average analysts' forecast of $124.94M by 5.38%. The company's EBITDA was $48.62M, beating the average prediction of $20.62M by 135.84%. ANI Pharmaceuticals's net income was $1.16M, missing the average estimation of $16.52M by -93.01%. The company's SG&A was $44.46M, beating the average forecast of $42.39M by 4.90%. Lastly, the company's EPS was $0.0601, missing the average prediction of $0.855 by -92.97%